Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

(Bloomberg) -- A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting coverage of the stock. Kepler Cheuvreux’s David Evans ...

Novo Nordisk A/S is following in rival Eli Lilly & Co.’s footsteps by selling its hit weight-loss drug Wegovy directly to US ...

Novo Nordisk is also pursuing other indications ... we are featuring today include Moody's Corp. (MCO), Diamondback Energy, Inc. (FANG) and Waste Management, Inc. (WM).